Overview

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Immutep S.A.
Immutep S.A.S.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab